Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Others

BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2026)

BridgeBio Pharma's Change in Receivables history spans 2 years, with the latest figure at $22.9 million for Q4 2025.

On a quarterly basis, Change in Receivables rose 440.2% to $22.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $134.7 million, a 4434.57% increase, with the full-year FY2025 number at $134.7 million, up 4434.57% from a year prior.
Change in Receivables hit $22.9 million in Q4 2025 for BridgeBio Pharma, down from $39.6 million in the prior quarter.
Over the last five years, Change in Receivables for BBIO hit a ceiling of $233.7 million in Q1 2024 and a floor of -$234.8 million in Q2 2024.